Kovogen

Mystic, CT 06355

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $1.22MM
First Award Date 09/27/06
Most Recent Award Date 09/01/10

Key Personnel

Last Name Name Awards Contact
Kovoor Abraham Kovoor 3
Celver Jeremy Phillip Celver 2

5 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-071
Budget: 09/01/10 - 08/31/13

DESCRIPTION (provided by applicant): This proposal describes the development of hyperpolarized-129Xenon (HP-Xe)-based probes for magnetic resonance imaging (MRI) of two biomarkers of inflammation and brain injury, the peripheral benzodiazepine receptor (PBR) and the neurotrophic protein, S100B. Molecular imaging (MI) is an emerging discipline th...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-071
Budget: 09/30/09 - 08/31/10

DESCRIPTION (provided by applicant): This proposal describes the development of hyperpolarized-129Xenon (HP-Xe)-based probes for magnetic resonance imaging (MRI) of two biomarkers of inflammation and brain injury, the peripheral benzodiazepine receptor (PBR) and the neurotrophic protein, S100B. Molecular imaging (MI) is an emerging discipline th...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-06-28
Budget: 08/01/07 - 07/31/09

DESCRIPTION (provided by applicant): The objective of this project is to develop a genetic test, involving the protein, RGS9, to identify patients that are at risk for developing tardive dyskinesia (TD) or L-DOPA induced dyskinesia (LID). Antipsychotic drugs have revolutionized the treatment of schizophrenia and psychotic disorders but a debilit...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-06-28
Budget: 09/27/06 - 07/31/07

DESCRIPTION (provided by applicant): The objective of this project is to develop a genetic test, involving the protein, RGS9, to identify patients that are at risk for developing tardive dyskinesia (TD) or L-DOPA induced dyskinesia (LID). Antipsychotic drugs have revolutionized the treatment of schizophrenia and psychotic disorders but a debilit...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-06-28
Budget: 09/27/06 - 07/31/07

DESCRIPTION (provided by applicant): The objective of this project is to develop a genetic test, involving the protein, RGS9, to identify patients that are at risk for developing tardive dyskinesia (TD) or L-DOPA induced dyskinesia (LID). Antipsychotic drugs have revolutionized the treatment of schizophrenia and psychotic disorders but a debilit...